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Akt and mitogen-activated protein kinase enhance C-type
lectin-like receptor 2-mediated platelet activation by
inhibition of glycogen synthase kinase 3a/b
A. J . MOROI and S . P . WATSON
Centre for Cardiovascular Science, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
To cite this article: Moroi AJ, Watson SP. Akt and mitogen-activated protein kinase enhance C-type lectin-like receptor 2-mediated platelet
activation by inhibition of glycogen synthase kinase 3a/b. J Thromb Haemost 2015; DOI: 10.1111/jth.12954.
Summary. Background: The C-type lectin-like receptor 2
(CLEC-2) and the collagen receptor glycoprotein (GP)VI
activate platelets through Src and Syk tyrosine kinases,
and phospholipase Cc2. The initial events in the two sig-
naling cascades, however, are distinct, and there are
quantitative differences in the roles of proteins down-
stream of Syk activation. The activation of Akt and mito-
gen-activated protein kinases (MAPKs) has been shown
to enhance platelet activation by GPVI, but their role in
CLEC-2 signaling is not known. Objectives: We sought to
investigate the role of the Akt and MAPK pathways in
platelet activation by CLEC-2. Results: The CLEC-2
agonist rhodocytin stimulated phosphorylation of Akt
and p38 and extracellular signal-related kinase (ERK)
MAPKs, but with a delay relative to Syk. Phosphoryla-
tion of these proteins was markedly inhibited in the com-
bined presence of apyrase and indomethacin, consistent
with the reported feedback action of ADP and thrombox-
ane A2 in CLEC-2 signaling. Phosphorylation of Akt and
phosphorylation of ERK were blocked by the phospho-
inositide 3-kinase (PI3K) inhibitor wortmannin and the
protein kinase C (PKC) inhibitor Ro31-8220, respectively,
whereas Syk phosphorylation was not altered. On the
other hand, both inhibitors reduced phosphorylation of
the Akt substrate glycogen synthase kinase 3a/b (GSK3a/
b). Phosphorylation of GSK3a/b was also blocked by the
Akt inhibitor MK2206, and reduced at late, but not early,
times by the MEK inhibitor PD0325901. MK2206 and
PD0325901 inhibited aggregation and secretion in
response to a low concentration of rhodocytin, which was
restored by GSK3a/b inhibitors. Conclusions: These
results demonstrate that CLEC-2 regulates Akt and
MAPK downstream of PI3K and PKC, leading to phos-
phorylation and inhibition of GSK3a/b, and enhanced
platelet aggregation and secretion.
Keywords: C-type lectin; glycogen synthase kinase 3;
mitogen-activated protein kinases; phosphatidylinositol
3-kinases; protein kinase B.
Introduction
C-type lectin-like receptor 2 (CLEC-2) is a C-type lectin-
like receptor that is highly expressed in platelets and
expressed at a low level in other hematopoietic cells [1–3].
The only known endogenous ligand for CLEC-2 is po-
doplanin, a sialomucin-like glycoprotein that is expressed
in a wide variety of cells outside of the vasculature [4].
CLEC-2 is also activated by the snake venom toxin rhod-
ocytin.
CLEC-2 signals through a similar pathway to the colla-
gen receptor gylcoprotein (GP)VI/FcRc, which utilizes an
immunoreceptor tyrosine-based activation motif (ITAM)
in the cytosolic tail of FcRc [5]. An ITAM has two con-
served YxxL sequences separated by 6–12 amino acids
that, when phosphorylated, bind to the tandem SH2
domains in Syk, inducing kinase activation. CLEC-2 has
a single YxxL motif, known as a hemITAM, which acti-
vates Syk through the bridging of two phosphorylated
receptors via its tandem SH2 domains. In contrast to
GPVI, the activation of CLEC-2 in human platelets is
critically dependent on the feedback actions of ADP and
thromboxane A2 (TxA2), and actin polymerization [6].
The activation of Syk by CLEC-2 or GPVI initiates a
signaling cascade of adapter and effector proteins that
culminates in the activation of phospholipase Cc2
(PLCc2) [7–9]. This signaling cascade is conserved
between the two receptors, although a number of quanti-
tative and qualitative differences have been reported,
including the ability of high concentrations of CLEC-2
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but not of GPVI agonists to activate platelets deficient in
the adapter protein SLP-76 [10].
The phosphoinositide 3-kinase (PI3K)–Akt pathway
has been shown to support platelet activation by GPVI
through the regulation of the serine/threonine kinase Akt
(also known as protein kinase B) [11]. Mouse and human
platelets express all three known isoforms of Akt, i.e.
Akt1, Akt2, and Akt3, and all have been shown to con-
tribute to platelet activation [12–16]. Akt family proteins
are regulated through phosphorylation of Thr308 and
Ser473 by phosphoinositide-dependent kinase 1 (PDK1)
and mammalian target of rapamycin complex 2, respec-
tively [12,17–20]. The generation of phosphatidylinositol
3,4,5-trisphosphate by PI3K recruits PDK1 and Akt to
the plasma membrane via their pleckstrin homology (PH)
domains, leading to PDK1-dependent phosphorylation of
Akt. In addition, Akt can be phosphorylated by protein
kinase C (PKC) and by Ca2+/calmodulin-dependent pro-
tein kinase kinase (CaMKK) independently of PI3K
[21–23]. Activation by collagen is impaired in mouse
platelets deficient in Akt1 [16], possibly as a consequence
of loss of phosphorylation of the inhibitory protein glyco-
gen synthase kinase 3a/b (GSK3a/b) [24]. However, inhi-
bition of GSK3a/b in human platelets has no effect on
activation by the synthetic GPVI agonist collagen-related
peptide (CRP), challenging this mechanism [13].
Mitogen-activated protein kinases (MAPKs) are
divided into four subgroups: extracellular signal-related
kinases (ERK), c-Jun N-terminal kinases (JNK), big
mitogen-activated protein kinase 1 (BMK1; ERK5), and
p38. Among these, ERK, JNK and p38 are expressed in
platelets, and are regulated by a wide range of receptors.
ERK is activated in response to collagen, and the MEK
inhibitor U0126 blocks activation by low concentrations
of collagen [25,26]. On the other hand, B€orsch-Haubold
et al. [27] demonstrated that the MEK inhibitor
PD98059 had no effect on platelet aggregation induced
by collagen, although this study was performed in the
presence of a cyclooxygenase inhibitor, as PD98059 also
inhibits this class of enzyme [28]. These results therefore
suggest that ERK may contribute to platelet activation
by GPVI through the regulation of thromboxane
formation.
In this study, we investigated the role of the PI3K–Akt
and MAPK pathways in platelet activation by CLEC-2
by using the pharmacologic inhibitors MK2206 and
PD0325901, which block Akt and the MAPK-activating
protein MEK, respectively. We show that Akt and ERK
support platelet aggregation in response to low concentra-
tions of the CLEC-2-activating snake toxin rhodocytin
through phosphorylation of GSK3a/b, thus preventing its
inhibitory action. Moreover, the PKC inhibitor Ro31-
8220 also reduces GSK3a/b phosphorylation. These
results demonstrate that CLEC-2 regulates GSK3a/b
phosphorylation downstream of Akt, ERK, and PKC,
thus enhancing platelet activation.
Materials and methods
Reagents and antibodies
Rhodocytin was purified from Calloselasma rhodostoma
venom as previously described [29]. Horm collagen was
from Takeda (Munich, Germany). Crosslinked CRP was
from R. Farndale (Cambridge University, UK). The
anti-phosphotyrosine mAb 4G10 was from Upstate
Biotechnology (TCS Biologicals, Buckingham, UK).
Anti-phospho-Akt (Thr308), anti-phospho-p38 (Thr180/
182), anti-phospho-Syk (Tyr352), anti-phospho-PLCc2
(Tyr1217) and anti-phospho-GSK3a/b (Ser21/9) were from
Cell Signaling Technology (New England Biolabs, Hitchin,
UK). Anti-Syk, anti-phospho-ERK1/2 (Thr202/Tyr204)
and anti-ERK2 were from Santa Cruz Biotechnology (Hei-
delberg, Germany). MK2206, CHIR-99021 and
PD0325901 were from Selleck Chemicals (Stratech, New-
market, UK). PRT-318 was provided by Portola Pharma-
ceuticals (San Francisco, CA, USA). All other reagents
were from Sigma-Aldrich (Poole, UK) or from previously
named sources [30].
Platelet preparation
All donors gave informed consent, and the study was
approved by the University of Birmingham ethical review
committee. Platelet preparation was performed as previ-
ously described [31]. Venous blood from healthy drug-free
volunteers was taken into 10% sodium citrate, and mixed
with 1 : 9 (v/v) acid citrate dextrose (120 mM sodium cit-
rate, 110 mM glucose, and 80 mM citric acid), and centri-
fuged at 200 9 g to obtain platelet-rich plasma (PRP).
Prostacyclin (0.5 lg mL1) was added, and PRP was centri-
fuged at 1000 9 g for 10 min to obtain a platelet pellet. The
platelets were washed once by resuspension in HEPES–Ty-
rode’s buffer (134 mM NaCl, 2.9 mM KCl, 0.34 mM Na2H-
PO4.12H2O, 12 mM NaHCO3, 20 mM HEPES, 1 mM
MgCl2, and 5.0 mM glucose [pH 7.3]) and further centrifu-
gation at 1000 9 g for 10 min in the presence of prostacy-
clin (0.5 lg mL1) and 1 : 9 (v/v) acid citrate dextrose. The
pellet of washed platelets was resuspended in a small volume
of the HEPES–Tyrode’s buffer, and then diluted to an
appropriate concentration for experimentation: a cell den-
sity of 2 9 108 mL1 was used for aggregation, and a cell
density of 5 9 108 mL1 was used for western blotting.
Western blotting
To inhibit aggregation, washed platelets were pretreated
with 9 lM integrilin (eptifibatide), unless otherwise men-
tioned. Samples of washed platelets (300 lL) were stimu-
lated with rhodocytin in an aggregometer at 1200 r.p.m.
and 37 °C. Platelets were pretreated for 15 min with the
following inhibitors (final concentrations indicated in
parentheses): apyrase (2 U mL1), indomethacin (10 lM),
© 2015 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.
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PRT-318 (5 lM), PP2 (10 lM), BAPTA-AM (10 lM),
wortmannin (100 nM), Ro31-8220 (5 lM), LY294002
(5 lM), MK2206 (1 lM), and PD0325901 (5 lM). An
equal concentration of dimethylsulfoxide (0.2%) was
added to the controls. Reactions were terminated by addi-
tion of an equal volume of ice-cold 2 9 lysis buffer
(300 mM NaCl, 20 mM Tris, 2 mM EGTA, 2 mM EDTA,
and 2% NP40 [pH 7.5]). The samples were diluted with
an equal volume of 2 9 sample buffer (4% SDS, 10% 2-
mercaptoethanol, 20% glycerol, and 50 mM Tris [pH
6.8]), separated by SDS-PAGE (10%), and transferred to
a poly(vinylidene difluoride) membrane. Western blotting
was performed with the indicated antibodies. Densitome-
try of the bands was performed with IMAGE J software
(NIH, Bethesda, MD, USA).
Platelet aggregation and ATP secretion
Aggregation was monitored by light transmission with a
Born lumi-aggregometer (Chronolog, Harvertown, PA,
USA). ATP secretion was measured with a luciferin/lucif-
erase substrate/enzyme mix (Chronolume).
Statistics
All experiments were performed three to five times, and
data are shown as means  standard errors of the mean.
Statistical analysis was performed with one-way ANOVA
followed by the Newman–Keuls test. A P-value of < 0.05
defined significant differences between test groups.
Results
The PI3K–Akt and MAPK pathways are activated by CLEC-2
In the present study, we investigated the role of the
PI3K–Akt and MAPK pathways in platelet activation by
CLEC-2. As shown in Fig. 1, rhodocytin stimulated phos-
phorylation of Akt, and p38 and ERK MAPKs, with a
delay of 30–90 s (Fig. 1A,B). Phosphorylation of the Akt
substrate, GSK3a/b, at its negative regulatory site
occurred in parallel with phosphorylation of Akt
(Fig. 1A,B). In contrast, robust phosphorylation of Syk
at the activation tyrosine, Tyr352 [32], occurred within
10–30 s (Fig. 1A,B), suggesting that this lies upstream of
phosphorylation of the Akt and MAPK pathways. Con-
sistent with this, phosphorylation of Akt and MAPK, as
well as of PLCc2, which has been previously shown to be
regulated downstream of Syk, by rhodocytin was blocked
by the Syk inhibitor PRT-318 and the Src inhibitor PP2
(Fig. S1A). Activation of the collagen receptor GPVI by
CRP was also associated with a delay in phosphorylation
of Akt, p38 and ERK relative to Syk (Fig. S2), as previ-
ously reported [33,34]. Phosphorylation of Akt and
MAPK by rhodocytin was maintained in the presence of
the aIIbb3 blocker integrilin, demonstrating that
phosphorylation is independent of outside-in signaling by
the integrin (Fig. S1A).
We have previously reported that the secondary agon-
ists ADP and TxA2 play a critical feedback role in the
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Fig. 1. The phosphoinositide 3-kinase–Akt and mitogen-activated
protein kinase pathways are activated after C-type lectin-like recep-
tor 2 stimulation. (A) Washed human platelets (5 9 108 mL1) were
pretreated with integrilin (9 lM). Platelets were then preincubated
with the vehicle (dimethylsulfoxide [DMSO]), and stimulated with
300 nM rhodocytin for the indicated times before extraction. Whole
cell lysates were analyzed for phosphorylation of Akt (Thr308), p38
(Thr180/182), extracellular signal-related kinase (ERK) (Thr202/
Tyr204), glycogen synthase kinase 3a/b (GSK3a/b) (Ser21/9) and
Syk (Tyr352) by western blotting. Total tyrosine phosphorylation
was detected with 4G10 mAb, and ERK2 was used as a loading con-
trol. (B) Densitometric measurements of phospho-Akt, phospho-p38,
phospho-ERK, phospho-Syk and phospho-GSK3b are expressed as
fold change over the basal control (DMSO only, no activation). The
figure is representative of three independent experiments. Data are
reported as the mean  standard error of the mean (n = 3).
*P < 0.05, **P < 0.01 and ***P < 0.001 as compared with the basal
phosphorylation level of each molecule.
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regulation of CLEC-2 signaling in human platelets [6]. In
line with this, the ATP scavenger apyrase and the cyclo-
oxygenase inhibitor indomethacin reduced phosphoryla-
tion of Akt and ERK by rhodocytin (300 nM), whereas
phosphorylation of p38 was only slightly inhibited (Fig.
2AI,B). In contrast, phosphorylation of Akt and ERK, as
well as of p38, was abolished in the presence of the com-
bination of indomethacin and apyrase, and phosphoryla-
tion of Syk and PLCc2 was markedly reduced (Fig. 2B).
These results are consistent with a pathway in which acti-
vation of CLEC-2 and Syk by rhodocytin is reinforced by
ADP and TxA2, as previously reported [6], leading to
robust phosphorylation of Akt, ERK, and p38 (Fig.
2AII,B). The presence of a residual level of phosphoryla-
tion of Syk and PLCc2, in contrast to the complete
blockade of Akt, ERK and p38 phosphorylation, suggests
that phosphorylation of the latter three proteins is medi-
ated predominantly by the combination of ADP and
TxA2.
Akt and ERK are phosphorylated downstream of PI3K and
PKC, respectively
We used pharmacologic inhibitors to further investigate
the regulation of Akt and MAPK by CLEC-2. The PI3K
inhibitor wortmannin abolished Akt phosphorylation by
CLEC-2 and inhibited phosphorylation of ERK at later
time points, but had a minimal effect on phosphorylation
of Syk and of p38 MAPK (Fig. 3A,B). On the other
hand, PLCc2 activation was dramatically reduced in the
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Fig. 2. Role of secondary mediators in C-type lectin-like receptor 2-mediated Akt and mitogen-activated protein kinase activation. Washed
human platelets (5 9 108 mL1) were pretreated with integrilin (9 lM). Platelets were then preincubated with 2 U mL1 apyrase or 10 lM
indomethacin (AI), apyrase + indomethacin (AII), or dimethylsulfoxide (DMSO). Platelets were stimulated with 300 nM rhodocytin for the
indicated times. Whole cell lysates were analyzed for phosphorylation of Akt (Thr308), p38 (Thr180/182), extracellular signal-related kinase
(ERK) (Thr202/Tyr204), glycogen synthase kinase 3a/b (GSK3a/b) (Ser21/9), Syk (Tyr352), and phospholipase Cc2 (PLCc2) (Tyr1217). ERK2
was used as a loading control. (B) Densitometric measurements of phospho-Akt, phospho-p38, phospho-ERK and phospho-GSK3b at 90 s
(left) and 300 s (right) after stimulation are expressed as fold increase over the basal level (DMSO, no rhodocytin). The blot shown is represen-
tative of three independent experiments. Data are reported as the mean  standard error of the mean (n = 3). *P < 0.05, **P < 0.01 and
***P < 0.001 as compared with the vehicle control.
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presence of wortmannin (Fig. 3A). In addition, wortman-
nin inhibited phosphorylation of GSK3a/b (Fig. 3A,B).
Similar results were obtained with a structurally distinct
PI3K inhibitor, LY294002 (data not shown).
In comparison, the PKC inhibitor Ro31-8220 blocked
phosphorylation of ERK at early and later times, but had
no effect on phosphorylation of p38 or Syk (Fig. 3A,B).
In addition, Ro31-8220 inhibited phosphorylation of Akt
and GSK3a/b at 300 s (Fig. 3A,B). A similar result was
obtained with apyrase-treated platelets (Fig. 2AI,B), sug-
gesting that loss of phosphorylation could be secondary
to inhibition of ADP secretion. On the other hand, at
90 s, Ro31-8220 blocked phosphorylation of GSK3a/b
but not of Akt (Fig. 3A,B), thereby dissociating GSK3a/
b and Akt phosphorylation, as previously shown in
thrombin-stimulated platelets [13]. Phosphorylation of
GSK3a/b and Akt was minimally restored at 300 s in the
presence of ADP, indicating that it could be partially
mediated by loss of ADP secretion, although this did not
reach significance (Fig. S1B,C). However, ADP had no
effect on GSK3a/b phosphorylation at 90 s. These results
therefore suggest that GSK3a/b phosphorylation is
mediated both directly and indirectly (through ADP
secretion) by PKC, with PKC having the predominant
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Fig. 3. The effects of phosphoinositide 3-kinase and protein kinase C inhibition on C-type lectin-like receptor 2 (CLEC-2)-mediated Akt and
mitogen-activated protein kinase phosphorylation. (A) Washed human platelets (5 9 108 mL1) were pretreated with integrilin (9 lM). Platelets
were then preincubated with 100 nM wortmannin, 5 lM Ro31-8220, or dimethylsulfoxide (DMSO). Platelets were stimulated with 300 nM rhod-
ocytin for the indicated times. Whole cell lysates were analyzed for phosphorylation of Akt (Thr308), p38 (Thr180/182), extracellular signal-
related kinase (ERK) (Thr202/Tyr204), glycogen synthase kinase 3a/b (GSK3a/b) (Ser21/9), Syk (Tyr352), and phospholipase Cc2 (PLCc2)
(Tyr1217). ERK2 was used as a loading control. (B) Densitometric measurements of phospho-Akt, phospho-p38, phospho-ERK and phospho-
GSK3b at 90 s (left) and 300 s (right) after stimulation are expressed as fold increase over the basal control (DMSO, or rhodocytin). The blot
shown is a representative of three independent experiments. Data are reported as the mean  standard error of the mean (n = 3). *P < 0.05
and **P < 0.01 as compared with the vehicle control.
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role. BAPTA-AM had no effect on Akt and MAPK
phosphorylation (Fig. S1A) at a concentration that has
been shown to block Ca2+ elevation at this platelet den-
sity [35,36]. This shows that CaMKK is dispensable for
phosphorylation.
Platelet aggregation and secretion induced by all con-
centrations of rhodocytin were markedly inhibited by
wortmannin and Ro31-8220 (Fig. 4A–C). GPVI-mediated
platelet activation was similarly inhibited by wortmannin
or Ro31-8220 (Fig. 4D; Fig. S3A).
These results demonstrate that Akt and ERK are regu-
lated downstream of PI3K and PKC, respectively, by
CLEC-2, and that both pathways are required for effi-
cient GSK3a/b phosphorylation. PI3K and PKC play a
critical role in platelet activation by all concentrations of
rhodocytin.
300 nMA
B C
D30 nM 10 nM
1 min
0
50
wtm
veh
wtm
wtm
veh
wtm
veh
Ag
gr
eg
at
io
n 
(%
)
1 min
0
CRP 0.3 µg mL–1
50
wtm
veh
Ag
gr
eg
at
io
n 
(%
)
300 nM 30 nM 10 nM
1 min
0
50
100
80
60
40
20
***
***
***
*** ***
***
*** ***
***
***
*** *** ***
**
0
0
Ve
hic
le
Wo
rtm
an
nin
Ro
31
-82
20
Ve
hic
le
Wo
rtm
an
nin
Ro
31
-82
20
1
2
3
4
3 10 30
Rhodocytin (nM)
60 100 300
AT
P 
se
cr
et
io
n 
(nM
/1×
10
8  
pl
t)
Ro31
Ro31
Ro31
Ro31
Ro31
veh
veh
100 nM
10 nM
veh veh
Ag
gr
eg
at
io
n 
(%
)
Ag
gr
eg
at
io
n 
(%
)
1 min
0
CRP 0.3 µg mL–1
50
veh
Ag
gr
eg
at
io
n 
(%
)
Fig. 4. The effects of phosphoinositide 3-kinase and protein kinase C inhibition on C-type lectin-like receptor 2-mediated platelet secretion and
aggregation. (A–D) Washed human platelets (2 9 108 mL1) preincubated with 100 nM wortmannin, 5 lM Ro31-8220 or dimethylsulfoxide
(DMSO) (vehicle control) were stimulated at 37 °C with the indicated dose of rhodocytin (A–C) or collagen-related peptide (CRP) (D), and
platelet aggregation (A, D) and ATP secretion (C) were measured for 5 min. Each aggregation tracing is representative of results obtained from
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or absence of wortmannin or Ro31-8220 was plotted as a function of rhodocytin concentration. (C) Quantification of peak platelet ATP release
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**P < 0.01 and ***P < 0.001 as compared with the vehicle control (DMSO). plt, platelets; Ro31, Ro31-8220; veh, vehicle; wtm, wortmannin.
© 2015 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.
6 A. J. Moroi and S. P. Watson
Akt and ERK enhance platelet activation by CLEC-2
We used selective inhibitors of the Akt and ERK path-
ways, MK2206 and PD0325901, respectively, to investi-
gate their role in platelet activation by CLEC-2. MK2206
binds to the PH domain of Akt, thereby inhibiting its
recruitment to the plasma membrane, and preventing
phosphorylation by PDK1. In line with this, MK2206
blocked phosphorylation of Akt and reduced phosphory-
lation of GSK3a/b at 90 s and 300 s (Fig. 5A,B). In
contrast, p38 phosphorylation was maintained in the
presence of MK2206 (Fig. 5A,B). Inhibition of ERK by
PD0325901 inhibited phosphorylation of Akt and
GSK3a/b at 300 s (Fig. 5A,B). Thus, ERK mediates
delayed phosphorylation of Akt and GSK3a/b. Phos-
phorylation of Syk and PLCc2 was maintained in the
presence of MK2206 and PD0325901, confirming that
activation of Akt and ERK lies downstream of Syk and
PLCc2 (Fig. 5A).
To investigate the functional significance of the Akt
and MAPK pathways, we monitored platelet aggregation
and secretion. MK2206 blocked aggregation and ATP
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secretion induced by a low concentration of rhodocytin
(10 nM), and very slightly delayed the onset of aggrega-
tion in response to an intermediate concentration
(30 nM). There was no inhibition of aggregation or secre-
tion in response to 300 nM rhodocytin (Fig. 6A–C).
The MEK inhibitor PD0325901 had a similar effect, with
inhibition of aggregation at a low concentration of rhod-
ocytin (10 nM), a slight delay in onset at an intermediate
concentration (30 nM), and no effect at a higher concen-
tration (Fig. 6A,B). ATP secretion was also inhibited by
PD0325901 in response to a low but not a high concen-
tration of rhodocytin (Fig. 6C). The start of aggregation
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at a low concentration of rhodocytin (10 nM) was delayed
relative to phosphorylation of Akt, ERK, and GSK3a/b,
which occurred after 90 s (Fig. 5A), further suggesting that
Akt and ERK regulate aggregation. Aggregation induced
by a low (0.3 lg mL1) but not a high (10 lg mL1) con-
centration of CRP was also partially reduced in the pres-
ence of MK2206 and PD0325901 (Fig. 6D; Fig. S3B).
Together, these results demonstrate that Akt and ERK
play a role in platelet activation induced by low concentra-
tions of CLEC-2 and GPVI receptor agonists.
GSK3a/b is the downstream effector for the PI3K–Akt and
MAPK pathways
The above results are consistent with a model in which
rhodocytin stimulates GSK3a/b phosphorylation at its
negative regulatory site downstream of Akt and ERK,
thereby inhibiting GSK3a/b activity. To investigate the
consequence of loss of phosphorylation of GSK3a/b on
platelet activation, we treated platelets with the GSK3a/b
inhibitors CHIR-99021 and SB216763. These are ATP
competitive inhibitors that block GSK3 activation but not
its phosphorylation. Consistent with the inhibitory action
of GSK3a/b, both inhibitors caused a small potentiation
of aggregation by rhodocytin (Fig. S4A). Furthermore,
inhibition of rhodocytin-induced platelet aggregation and
secretion by MK2206 was reversed in the presence of
CHIR-99021 (Fig. 7A; Fig. S4C) and SB216763 (Fig. S4B).
CHIR-99021 and SB216763 also rescued aggregation
and secretion of PD0325901-treated platelets (Fig. 7B;
Fig. S4B,C). In contrast, inhibition of platelet aggregation
or secretion after wortmannin treatment was not rescued
by CHIR-99021 (Fig. 7C; Fig. S4C). This indicates that
PI3K regulates platelet activation through one or more
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Fig. 7. Glycogen synthase kinase 3a/b is the downstream effector for Akt and mitogen-activated protein kinase activation. Washed human
platelets (2 9 108 mL1) were preincubated with MK2206 (A), 5 lM PD0325901 (B), 100 nM wortmannin (C) or dimethylsulfoxide (vehicle
control) in the presence or absence of CHIR-99021, and stimulated with 10 nM rhodocytin at 37 °C; and platelet aggregation was then mea-
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additional pathways to that of regulation of GSK3a/b.
Interestingly, we did not observe potentiation of platelet
aggregation by low concentrations of CRP (0.1 lg mL1
and 0.3 lg mL1) in the presence of CHIR-99021 or
SB216763 (Fig. S5A), but observed inhibition of the
response to collagen (Fig. S5B), as previously reported
[15,37].
To verify that GSK3a/b is regulated downstream of
Akt and ERK in CLEC-2 signaling independently of
aIIbb3, we treated platelets with integrilin before stimula-
tion and monitored ATP secretion. Rhodocytin-induced
secretion was blocked in the presence of Akt and MEK
inhibitors, and this was rescued in the presence of CHIR-
99021, confirming that the effect of inhibition of GSK3a/
b on platelet activation is integrin-independent (Fig.
S5C). This is consistent with the observation in Fig. S1A
that activation of Akt and MAPK by CLEC-2 is also in-
tegrin-independent (Fig. S1A).
Discussion
In this study, we have demonstrated that CLEC-2
activates the PKC, PI3K–Akt and ERK pathways,
leading to phosphorylation of GSK3a/b at its negative
regulatory site, and loss of its inhibitory action, thereby
enhancing platelet activation at low concentrations of
rhodocytin. Akt regulates phosphorylation of GSK3a/b at
90 s and 300 s, whereas ERK only regulates phosphoryla-
tion at the latter time. This study therefore adds to the
growing evidence that GSK3a/b mediates a weak, constit-
utive inhibitory signal that regulates platelet activation by
threshold agonist concentrations, and that this is inhibited
by PKC-mediated, Akt-mediated and MAPK-mediated
phosphorylation of GSK3a/b, with the effect of PKC
being mediated in part through secretion of ADP.
The contribution of GSK3a/b to platelet activation has
been controversial, as it appears to vary between agonists
and is dependent on experimental conditions. For exam-
ple, in the present study we showed that inhibition of
GSK3a/b had a minimal effect on platelet activation
by CRP, whereas collagen-mediated activation was
significantly reduced, as previously reported [13,15,37].
This difference may be related to the much greater feed-
back role of ADP and TxA2 in platelet activation by colla-
gen than in platelet activation by CRP, which may
accentuate the effect of other mechanisms of platelet regu-
lation. Alternatively, collagen may regulate GSK3a/b
downstream of a2b1, which is not activated by CRP. A
concern regarding pharmacologic inhibitors is that of off-
target effects. In consideration of this, we have shown that
two structurally different inhibitors of GSK3a/b potentiate
platelet aggregation, thereby strengthening the argument
that GSK3a/b is a negative regulator of CLEC-2 signaling
but that it has a negligible effect on GPVI signaling.
The explanation for the differential time course of phos-
phorylation of GSK3a/b by rhodocytin, with Akt inducing
significant phosphorylation at both 90 s and 300 s, and
ERK inducing it at later times, is not known. However, it
is noteworthy that, although not significant, a clear trend
towards reduction in GSK3a/b phosphorylation was seen
at 90 s in the presence of PD0325901, and this may explain
why inhibition of ERK activation by PD0325901 also
reduces platelet aggregation by CLEC-2 stimulation. In
line with these results, ERK has also been shown to phos-
phorylate GSK3a/b in other cells [38,39]. Moreover, inhi-
bition of GSK3a/b can rescue platelets from the inhibitory
action of Akt and MEK inhibitors with or without integrin
activation, confirming GSK3a/b as a functional effector
that lies downstream of Akt and ERK upon CLEC-2 acti-
vation. In contrast, we were unable to rescue the inhibitory
effect of the PI3K inhibitor wortmannin with a GSK3a/b
inhibitor, suggesting that PI3K regulates additional path-
ways to those regulated by Akt. Consistent with this, wort-
mannin also inhibits aggregation at high concentrations of
rhodocytin, whereas MK2206 only inhibits aggregation at
low concentrations of this agonist. In this study, we have
also shown that the PKC inhibitor Ro31-8220 significantly
reduces GSK3a/b phosphorylation independently of Akt
and that this could not be fully rescued by the addition of
ADP. This shows that PKC mediates phosphorylation of
GSK3a/b through direct and indirect (i.e. ADP and Akt
regulation) mechanisms, as previously reported for throm-
bin stimulation [13].
The molecular mechanism through which GSK3a/b
regulates CLEC-2-mediated platelet activation could be
through phosphorylation of its substrate, MAP-tau. Inhibi-
tion of GSK3b leads to a reduction in MAP-tau phosphor-
ylation in thrombin-simulated platelets [40]. MAP-tau has
been shown to play a critical role in microtubule polymeri-
zation in other cells [41,42]. GSK3a/b might therefore
regulate granule secretion in platelets through microtubule
polymerization.
To date, there have been opposing reports on the impor-
tance of MAPK in platelets. The p38 inhibitor SB203580
has been reported to inhibit platelet aggregation induced
by low concentrations of U46619 and collagen, although it
is unclear whether this is attributable to off-target effects
on cyclooxygenase [43]. Later, it was shown that a second
p38 inhibitor, SB202190, also inhibits platelet activation
[44]. Several laboratories have reported that MEK inhibi-
tors suppress collagen-mediated, thrombin-mediated, von
Willebrand factor-mediated and ADP-mediated platelet
activation [25,44–46], whereas others have reported no
effect [27]. In our study, we used the selective MEK inhibi-
tor PD0325901, and showed that ERK inhibition inhibits
platelet activation in response to low concentrations of
both rhodocytin and CRP, although this effect is readily
overcome at higher concentrations of both ligands.
We have previously shown that, together, secondary
mediators such as ADP and TxA2 are essential for robust
activation of CLEC-2 [6]. Consistent with this, we have
shown that ADP and TxA2 regulate phosphorylation of
© 2015 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.
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Akt and ERK by CLEC-2. In our previous study [6], we
used 30 nM rhodocytin, and found complete blockade of
CLEC-2 activation in the presence of apyrase and indo-
methacin. In the present study, we observed a weak but
significant increase in phosphorylation of Syk and PLCc2
in response to a 10-fold higher concentration of rhodocy-
tin (300 nM). This demonstrates that the initial weak acti-
vation of CLEC-2 by the snake toxin is significantly
enhanced by the feedback action of ADP and TxA2. Fur-
thermore, we have shown that blocking the effect of
secreted ADP by apyrase or of secretion by Ro31-8220
has a pronounced effect on Akt phosphorylation at 300 s
but not at 90 s, which indicates two pathways of regula-
tion, one of which is mediated by secretion of ADP. As
CLEC-2 activation is markedly inhibited in the presence
of apyrase and indomethacin, however, we cannot readily
compare the importance of CLEC-2 and ADP in the reg-
ulation of Akt and MAPK phosphorylation. However, it
noteworthy that, whereas ADP and TxA2 are important
for reinforcing CLEC-2 activation, neither ADP nor
TxA2 induces CLEC-2 phosphorylation [6].
In conclusion, we have shown that the Akt and MAPK
pathways play a critical role in platelet activation at
threshold levels of CLEC-2 activation through phosphor-
ylation of GSK3a/b, thus blocking its inhibitory action.
PKC also regulates GSK3a/b phosphorylation at early
times, independently of Akt.
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